Theriva Biologics (NYSEAMERICAN:TOVX) Trading 2.6% Higher – Here’s Why

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX)’s share price was up 2.6% during mid-day trading on Tuesday . The stock traded as high as $0.2472 and last traded at $0.2401. Approximately 962,701 shares traded hands during trading, a decline of 64% from the average daily volume of 2,703,499 shares. The stock had previously closed at $0.2340.

Wall Street Analyst Weigh In

Separately, Maxim Group upgraded shares of Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a research report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Theriva Biologics has an average rating of “Buy” and a consensus target price of $1.00.

Theriva Biologics Trading Up 2.6%

The company has a debt-to-equity ratio of 0.11, a current ratio of 1.63 and a quick ratio of 1.63. The stock has a 50-day moving average price of $0.28 and a two-hundred day moving average price of $0.24. The stock has a market cap of $8.10 million, a PE ratio of -0.01 and a beta of 1.09.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its earnings results on Tuesday, May 5th. The company reported ($0.05) EPS for the quarter. The company had revenue of $0.30 million during the quarter.

Institutional Trading of Theriva Biologics

An institutional investor recently raised its stake in Theriva Biologics stock. Geode Capital Management LLC grew its position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 212,087 shares of the company’s stock after acquiring an additional 183,878 shares during the quarter. Geode Capital Management LLC owned about 0.63% of Theriva Biologics worth $45,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.